• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Blackline Safety appoints former Sierra Wireless CEO, Jason W. Cohenour, to Board of Directors

    9/13/22 9:17:00 AM ET
    $CAMP
    $RFIL
    $SWIR
    Electrical Products
    Technology
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Get the next $CAMP alert in real time by email

    Mr. Cohenour brings 30+ years of executive leadership experience in IoT, mobile communications and semiconductors to Blackline

    Blackline Safety Corp. (TSX:BLN), a global leader in connected safety technology, today announced the appointment of Jason W. Cohenour, former President and CEO at Sierra Wireless, as a new member of its Board of Directors.

    Mr. Cohenour brings many years of executive leadership, sales, operations, and international M&A experience to the Blackline Safety Board. He previously served as President, CEO, and Director at Sierra Wireless, Inc. (TSX:SW, NASDAQ:SWIR) from 2005 to 2018. While CEO, Mr. Cohenour led a successful business turn-around, resulting in revenue growth of nearly 800% to over CAD $1 Billion. Mr. Cohenour also serves on the boards of CalAmp (NASDAQ:CAMP) and RF Industries (NASDAQ:RFIL).

    "Having followed Blackline for a number of years as a successful hardware-enabled SaaS company with over 1,000 customers around the world, I am enthusiastic to support the business at this stage of its evolution," said Jason Cohenour. "I look forward to joining the Board and working with the Blackline team to help the company execute with confidence and further its mission to ensure workers get home safe."

    "Adding Jason to our Board at this pivotal time is ideal timing for Blackline," said Cody Slater, Chair and CEO of Blackline Safety. "Jason's executive leadership experience, background in IoT, mobile communication and semiconductors through his work at Sierra, and guidance as a director in public companies will have a direct impact as Blackline matures into its next stage of sustainable growth."

    With Mr. Cohenour's appointment this brings Blackline Safety's Board of Directors to eight. Other members include CEO and Chair, Cody Slater and six independent Directors: Cheemin Bo-Linn, Dr. John Finbow, Brad Gilewich, Michael Hayduk, Robert Herdman, and Barbara Holzapfel. Each of Blackline's Board members are seasoned business veterans who offer significant corporate leadership experience in the technology, industrial, software, marketing and business operations sectors. For more information on Blackline Safety's management team, please visit www.blacklinesafety.com/about/our-team.

    About Blackline Safety: Blackline Safety is a technology leader driving innovation in the industrial workforce through IoT. With connected safety devices and predictive analytics, Blackline enables companies to drive towards zero safety incidents and improved operational performance. Blackline provides wearable devices, personal and area gas monitoring, cloud-connected software and data analytics to meet demanding safety challenges and enhance overall productivity for organizations with coverage in more than 100 countries. Armed with cellular and satellite connectivity, Blackline provides a lifeline to tens of thousands of people, having reported over 185 billion data-points and initiated over five million emergency alerts. For more information, visit BlacklineSafety.com and connect with us on Facebook, Twitter, LinkedIn and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005548/en/

    Get the next $CAMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAMP
    $RFIL
    $SWIR

    CompanyDatePrice TargetRatingAnalyst
    CAMP4 Therapeutics Corporation
    $CAMP
    11/5/2024Outperform
    William Blair
    CAMP4 Therapeutics Corporation
    $CAMP
    11/5/2024$18.00Overweight
    Piper Sandler
    CAMP4 Therapeutics Corporation
    $CAMP
    11/5/2024$23.00Overweight
    JP Morgan
    CAMP4 Therapeutics Corporation
    $CAMP
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    Sierra Wireless Inc.
    $SWIR
    8/3/2022Buy → Hold
    Canaccord Genuity
    Sierra Wireless Inc.
    $SWIR
    4/19/2022Outperform
    William Blair
    Sierra Wireless Inc.
    $SWIR
    2/23/2022$21.50 → $24.00Buy
    B. Riley Securities
    CAMP4 Therapeutics Corporation
    $CAMP
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    More analyst ratings

    $CAMP
    $RFIL
    $SWIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Bibisi Ray Michael covered exercise/tax liability with 243 shares, decreasing direct ownership by 0.46% to 52,258 units (SEC Form 4)

      4 - R F INDUSTRIES LTD (0000740664) (Issuer)

      4/14/25 6:31:20 PM ET
      $RFIL
      Electrical Products
      Technology
    • Chief Financial Officer Yin Peter covered exercise/tax liability with 310 shares, decreasing direct ownership by 0.26% to 118,830 units (SEC Form 4)

      4 - R F INDUSTRIES LTD (0000740664) (Issuer)

      4/14/25 6:30:23 PM ET
      $RFIL
      Electrical Products
      Technology
    • CEO Dawson Robert D covered exercise/tax liability with 671 shares, decreasing direct ownership by 0.22% to 303,357 units (SEC Form 4)

      4 - R F INDUSTRIES LTD (0000740664) (Issuer)

      4/14/25 6:29:35 PM ET
      $RFIL
      Electrical Products
      Technology

    $CAMP
    $RFIL
    $SWIR
    SEC Filings

    See more
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/16/25 6:28:22 AM ET
      $CAMP
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP
    • SEC Form 10-Q filed by CAMP4 Therapeutics Corporation

      10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:26:54 PM ET
      $CAMP

    $CAMP
    $RFIL
    $SWIR
    Leadership Updates

    Live Leadership Updates

    See more
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalAmp Appoints Chris Adams as President and Chief Executive Officer

      IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

      1/8/24 6:30:00 AM ET
      $CAMP

    $CAMP
    $RFIL
    $SWIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Holdsworth Mark Keith bought $70,805 worth of shares (15,000 units at $4.72), increasing direct ownership by 16% to 106,953 units (SEC Form 4)

      4 - R F INDUSTRIES LTD (0000740664) (Issuer)

      3/31/25 6:57:39 PM ET
      $RFIL
      Electrical Products
      Technology
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP

    $CAMP
    $RFIL
    $SWIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP
    • JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

      JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

      11/5/24 6:14:20 AM ET
      $CAMP

    $CAMP
    $RFIL
    $SWIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th

      5/16/25 6:00:00 AM ET
      $CAMP
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP
    • CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three

      4/28/25 4:30:00 PM ET
      $CAMP

    $CAMP
    $RFIL
    $SWIR
    Financials

    Live finance-specific insights

    See more
    • RF Industries Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      SAN DIEGO, CA / ACCESS Newswire / January 16, 2025 / RF Industries, Ltd, (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced fourth quarter and fiscal year 2024 financial results for the fiscal year ended October 31, 2024.Fourth Quarter Fiscal 2024 Highlights and Operating Results:Net sales were $18.5 million; an increase of 16% from $15.9 million year-over-year and a 10% increase from $16.8 million in the third fiscal quarterBacklog of $19.5 million at year-end on fourth quarter bookings of $17.9 million. As of today, the backlog stands at $14.9 millionGross profit margin was 31.3% up from 28.4% in the prior year quarterOperating income

      1/16/25 4:02:00 PM ET
      $RFIL
      Electrical Products
      Technology
    • RF Industries to Report Fourth Quarter and Fiscal Year 2024 Financial Results on January 16

      SAN DIEGO, CA / ACCESSWIRE / December 19, 2024 / RF Industries, Ltd, (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the close of the market on Thursday, January 16, 2025.The Company will host a conference call and live webcast on January 16, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time) to discuss its financial results.To access the live call, dial 888-506-0062 (US and Canada) or 973-528-0011 (International) and give the participant access code 331321.A live and archived webcast of the conference call will be accessible on the investor rela

      12/19/24 7:00:00 AM ET
      $RFIL
      Electrical Products
      Technology
    • RF Industries Reports Third Quarter Fiscal Year 2024 Financial Results

      SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / RF Industries, Ltd, (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced third quarter fiscal year 2024 financial results for the quarter ended July 31, 2024.Third Quarter Fiscal Year 2024 Highlights and Operating Results:Net sales were $16.8 million; up 4.5% from $16.1 million in the second quarter of fiscal 2024 and up 7.6% from $15.7 million in the prior-year third quarter.Backlog of $20.1 million at the end of the third quarter on bookings of $18.9 million. As of today, the backlog stands at $19.5 million.Gross profit margin was 29.5%, up from 24.4% in the prior year period.Operating lo

      9/16/24 4:02:00 PM ET
      $RFIL
      Electrical Products
      Technology

    $CAMP
    $RFIL
    $SWIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP